Li K David, Salama Mohamed E
Hematopathology, Department of Pathology, University of Utah/ARUP Laboratories, 500 Chipeta Way, 115-G04, Salt Lake City, UT 84108, USA.
Hematopathology, Department of Pathology, University of Utah/ARUP Laboratories, 500 Chipeta Way, 115-G04, Salt Lake City, UT 84108, USA.
Surg Pathol Clin. 2016 Mar;9(1):177-87. doi: 10.1016/j.path.2015.09.006.
This article highlights the most common morphologic features identified in the bone marrow after chemotherapy for hematologic malignancies, growth-stimulating agents, and specific targeted therapies. The key is to be aware of these changes while reviewing post-therapeutic bone marrow biopsies and to not mistake reactive patterns for neoplastic processes. In addition, given the development and prevalent use of targeted therapy, such as tyrosine kinase inhibitors and immune modulators, knowledge of drug-specific morphologic changes is required for proper bone marrow interpretation and diagnosis.
本文重点介绍了血液系统恶性肿瘤化疗、生长刺激剂及特定靶向治疗后骨髓中最常见的形态学特征。关键在于在复查治疗后的骨髓活检时要知晓这些变化，且不要将反应性模式误认为肿瘤性病变。此外，鉴于靶向治疗（如酪氨酸激酶抑制剂和免疫调节剂）的发展及广泛应用，为了正确解读和诊断骨髓，需要了解药物特异性的形态学变化。
